Press Releases

 Filter by Provider

Clean Energy Fuels Corp. (NASDAQ: CLNE) (“Clean Energy” or the “Company”) today announced its operating results for the first quarter of 2025.

Olo Inc. (NYSE:OLO) (“Olo” or the “Company”), a leading open SaaS platform for restaurants, today announced financial results for the first quarter ended March 31, 2025.

Golden Entertainment, Inc. (NASDAQ: GDEN) (“Golden Entertainment” or the “Company”) today reported financial results for the first quarter ended March 31, 2025. In addition, on May 6, 2025, the Company’s Board of Directors authorized the Company’s next recurring quarterly cash dividend of $0.25 per share of the Company’s outstanding common stock payable on July 9, 2025 to shareholders of record as of June 25, 2025.

Mattel, Inc. (NASDAQ: MAT) today announced the appointment of Paul Ruh as Chief Financial Officer, effective May 19, 2025. Ruh succeeds Mattel’s current CFO Anthony DiSilvestro, who announced his retirement in January. DiSilvestro will continue to serve as an advisor to the company through August 15, 2025, to ensure a seamless transition of responsibilities. Ruh will report to Ynon Kreiz, Chairman and Chief Executive Officer of Mattel.

Affirm Holdings, Inc. (NASDAQ: AFRM) (“Affirm” or the “Company”), the payment network that empowers consumers and helps merchants drive growth, today reported financial results for its fiscal 2025 third quarter ended March 31, 2025. The results, which include a shareholder letter furnished to the U.S. Securities and Exchange Commission on Form 8-K, can be found in the “Events and Presentations” section of the Company’s investor relations website at https://investors.affirm.com/.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024.

Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the second quarter of fiscal year 2025.

Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced the appointment of Bill Scannell to its Board of Directors, effective May 7, 2025.

Good Times Restaurants Inc. (Nasdaq: GTIM), operator of the Bad Daddy’s Burger Bar and Good Times Burgers & Frozen Custard restaurant brands, today reported financial results for the fiscal 2025 second quarter.

Company to Host Quarterly Conference Call at 5:00 P.M. ET on May 8, 2025

MIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today reported financial results for the quarter ended March 31, 2025 and provided a business update.

Q1 Revenue of $6.3 million, growth year over year of 24%

FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025.

IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for the Internet of Things (IoT) solutions enabling Artificial Intelligence (AI) Edge Intelligence, today reported results for its third quarter of fiscal 2025.

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.  

MIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, announced its participation at the following upcoming conferences:

AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Amprius Technologies, Inc. ("Amprius"), (NYSE: AMPX), a leader in next-generation lithium-ion batteries with its Silicon Anode Platform, today announced its business and financial results for the first quarter ended March 31, 2025.

George Town, Grand Cayman--(Newsfile Corp. - May 8, 2025) - StoneCo Ltd. (Nasdaq: STNE) ("Stone" or the "Company") today reported...

Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025

PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025.

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Dune Acquisition Corporation II (the “Company”) announced today the closing of its initial public offering of 14,375,000 units, including the exercise in full of the underwriters’ over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $143,750,000. The units are listed on the Nasdaq Global Market (the “Nasdaq”) and commenced trading under the ticker symbol “IPODU” on May 7, 2025. Each unit consists of one Class A ordinary share and three-quarters of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share. After the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “IPOD” and “IPODW,” respectively.

SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025.

LITTLE ROCK, Ark., May 08, 2025 (GLOBE NEWSWIRE) -- Westrock Coffee Company (Nasdaq: WEST) (“Westrock Coffee” or the “Company”) today reported financial results for the first quarter ended March 31, 2025.

~ Revenue up 34% Year-over-Year to $23.7 Million ~

WASHINGTON, May 08, 2025 (GLOBE NEWSWIRE) -- IBEX Limited (“ibex”), a leading provider in global business process outsourcing and end-to-end customer engagement technology solutions, today announced financial results for its third fiscal quarter ended March 31, 2025.

Marketplace revenue grew 13% YoY

MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025.

Q1 2025 Revenue of $160 million, up 11% Year-Over-YearQ1 2025 Net Income of $62 million including $80 million of non-cash gainsQ1 2025 Adjusted EBITDA of $4.1 million improved $6.4 million Year-Over-Year

LONG BEACH, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the first quarter ended March 31, 2025 (“Q1 2025”).

EMERYVILLE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q1 2025 financial results, provided operational highlights and outlined expected upcoming milestones.

VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today reported financial results for the three months ended March 31, 2025 and provided a summary of recent business highlights.

CULVER CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, will hold a conference call and webcast on Wednesday, May 14, 2025 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the first quarter ended March 31, 2025.

Proprietary brand sales increased to 32.0% as a percentage of Cultivation and Gardening net sales

Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML

TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the first quarter ended March 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). 

Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date

SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025.

DULUTH, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Fox Factory Holding Corp. (NASDAQ: FOXF) (“FOX” or the “Company”), a premium brand and a global leader in the design, engineering and manufacturing of performance-defining products and systems for customers worldwide, today reported financial results for the first fiscal quarter ended April 4, 2025.

Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025;Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025

– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 –

Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025

— Strong revenue growth and well-positioned ahead of the global trade uncertainty —

First Quarter Revenue Exceeded Guidance

-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 --

CHICAGO, May 08, 2025 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its first quarter ended March 31, 2025.

SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWIRE) -- Brilliant Earth Group, Inc. (“Brilliant Earth” or the “Company”) (NASDAQ: BRLT), an innovative, global leader in ethically sourced fine jewelry, today announced that the Company will participate in the B. Riley Securities 25th Annual Investor Conference being held at the Ritz-Carlton, Marina Del Rey in Marina Del Rey, California.

Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway across multiple markets

Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C-peptide production post-transplant

Board of Directors Declared Total Dividends of $0.54 per Share for Second Quarter 2025Base Dividend of $0.43 and Supplemental Dividend of $0.11 Per Share